Related references
Note: Only part of the references are listed.9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Giovanni Targher et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
Amos Baruch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Steven A. Kliewer et al.
CELL METABOLISM (2019)
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
Edgar D. Charles et al.
OBESITY (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats
Umit Yilmaz et al.
JOURNAL OF PHYSIOLOGICAL SCIENCES (2018)
FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes
Mark Z. Chen et al.
MOLECULAR METABOLISM (2017)
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
Albert M. Kim et al.
DIABETES OBESITY & METABOLISM (2017)
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar et al.
CELL METABOLISM (2016)
FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver
Stephanie von Holstein-Rathlou et al.
CELL METABOLISM (2016)
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
Janki Patel et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Epidemiological Perspectives of Diabetes
Ziqi Tao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Glucocorticoids Regulate the Metabolic Hormone FGF21 in a Feed-Forward Loop
Rucha Patel et al.
MOLECULAR ENDOCRINOLOGY (2015)
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
Ganesh Kolumam et al.
EBIOMEDICINE (2015)
Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice
Zhuofeng Lin et al.
CELL METABOLISM (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Angie L. Bookout et al.
NATURE MEDICINE (2013)
Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
Murielle M. Veniant et al.
ENDOCRINOLOGY (2012)
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Anna Kotronen et al.
GASTROENTEROLOGY (2009)
Cortisol secretion in patients with type 2 diabetes - Relationship with chronic complications
Iacopo Chiodini et al.
DIABETES CARE (2007)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
GC Farrell et al.
HEPATOLOGY (2006)
Reproducibility, power and validity of visual analogue scares in assessment of appetite sensations in single test meal studies
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
Share Paper
